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Abstract
Background: Osteoprotegerin (OPG) is a member of the tumor necrosis factor receptor superfamily and suggested
as a marker of atherosclerosis. However, little is known about the association between plasma OPG levels and lower
extremity arterial disease. We investigated whether plasma OPG levels were associated with the presence and
severity of lower extremity arterial disease in patients with type 2 diabetes.
Methods: This was a study of 712 patients with type 2 diabetes aged 40 years or older. Plasma OPG was measured
using ELISA. The lower extremity arterial disease was diagnosed by high-frequency color Doppler ultrasonic.
Results: Of 712 patients, 505 (70.9 %) had lower extremity arterial stenosis. OPG levels were significantly increased
in patients with lower extremity arterial stenosis [1.89 (1.48-2.41) vs. 2.39 (1.82-3.33) ng/mL, p < 0.001]. Plasma OPG
levels increased gradually with increasing severity of lower extremity arterial stenosis (p < 0.001 for trend), after
adjustment for traditional cardiovascular risk factors such as age, gender, smoking, total cholesterol, high-density
lipoprotein (HDL) cholesterol, C-reactive protein (CRP), body mass index (BMI), systolic blood pressure(SBP). The risk
of lower extremity arterial disease was increased (OR = 1.17, 95 % CI 1.09 –1.28, p < 0.001) with each standard
deviation (SD) higher level of OPG in patients with type 2 diabetes after adjustment for traditional CVD risk factors.
Conclusions: Plasma OPG levels were significantly associated with the presence and severity of lower extremity
arterial disease. Our results suggest that OPG is an important plasma biomarker of lower extremity arterial disease in
type 2 diabetes.
Backgrounds
Osteoprotegerin (OPG) is a soluble member of the
TNF–receptor superfamily and act as decoy receptor
for both the receptor activator of nuclear factor-B
ligand (RANK–L) and the TNF–related apoptosis in-
ducing ligand (TRAIL), two cytokines of the TNF–
family [1]. OPG is produced by a variety of tissues,
including the cardiovascular system, lung, kidney, and
immune tissues, as well as bone, and that the expres-
sion and production of OPG are regulated by various
cytokines and hormones [2].
Recent studies have indicated that OPG also acts as an
important regulatory molecule in vascular disease, such
as arterial calcification and atherosclerosis [3–5]. The
function of OPG in the arterial wall is not known, but it
has been suggested that the molecule acts as a vascular
calcification inhibitor due to the fact that OPG knock-out
mice develop arterial calcifications [6]. Atherosclerosis is
now understood to be an inflammatory disease, and not
merely the result of the passive accumulation of lipids
within arterial walls [7]. OPG is expressed in vascular cells
such as coronary smooth muscle cells and endothelial cells
in vitro. In endothelial cells, OPG has been demonstrated
to act as an anti-apoptotic factor. Moreover, OPG immuno-
reactivity was demonstrated not only in the nondiseased
vessel wall, but also in early atherosclerotic lesions in
human tissues. These findings suggested that OPG may
play a pivotal role in the development of vascular
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disease. A clinical study reported that there was a sig-
nificant correlation between elevated serum OPG levels
and cardiovascular mortality, suggesting that OPG may
contribute to the progression of coronary artery disease
(CAD), and that they were increased in elderly people
and in diabetic patients [8].
Several studies have suggested that circulating OPG
levels is positively associated with peripheral arterial
disease [9, 10], which defined using ankle brachial index
(ABI), although data is inconsistent in recent meta ana-
lysis [11]. However, little is known about the association
between plasma OPG levels and lower extremity arterial
disease, which diagnosed by ultrasonic evaluation, in
patients with type 2 diabetes. In this study, we investi-
gated whether plasma OPG levels were associated with
the presence and severity of lower extremity arterial dis-
ease in patients with type 2 diabetes.
Methods
Patients
Subjects were recruited from the Department of
Endocrinology at Xinhua Hospital Affiliated to Shanghai
Jiaotong University between 2013 and 2014. All unre-
lated subjects with T2DM who attended the Diabetes Clinic
at the Xinhua Hospital were recruited consecutively to
participate in a prospective study to identify the risk factors
predisposing to the development of diabetic complications.
Each visit comprised clinical assessments and laboratory
investigations to determine the control of diabetes and
related cardiovascular risk factors, and the presence of
diabetic complications. Diabetes was defined according to
the 2008 American Diabetes Association diagnostic criteria
(MM) [12]. Subjects with arteriovenous grafts/shunts,vas-
culitis, chronic kidney disease, cerebral infarction, coron-
ary artery disease, malignancies, or with immunological
diseases, osteoporosis and subjects receiving systemic
glucocorticoids or immunosuppressants were excluded
from the study. A total of 712 T2DM subjects, who
attended regular visits at least twice a year, with the latest
follow-up in or before October 2014, were enrolled in the
study. Of these, 505 patients with lower extremity arter-
ial stenosis and 207 patients without lower extremity ar-
terial stenosis. Written informed consent was obtained
from all the participants. The study was approved by the
Institutional Review Broad of Xinhua Hospital Affiliated
to Shanghai Jiaotong University School of Medicine.
Biochemical measurements and clinical data collection
Peripheral venous blood samples were collected after an
overnight fast. The fasting plasma glucose(FPG) was mea-
sured with the use of the glucose oxidase method on an
auto-analyzer (Modular P800; Roche, Basel, Switzerland).
Triglycerides, total cholesterol, LDL-cholesterol, HDL-
cholesterol, and serum uric acid were measured using
chemiluminescence methods on the auto-analyzer (Modu-
lar E170; Roche). HbA1c was measured with the use of the
Chromatography method on an auto-analyzer (D10;
Bio-Rad, USA). Age and history of cigarette use were
assessed through an interview preceding the physical exam-
ination. We defined “smoking” as the current smokers,
who smoke at least one cigarette per day.
Anthropometric parameters were measured in all sub-
jects. Hypertension was defined by systolic blood pressure
(SBP) ≥ 140 mmHg, diastolic blood pressure (DBP) ≥
90 mmHg, the current use of antihypertensive treatment,
or a combination of the three. Three blood pressure record-
ings were obtained from the right arm of patients in a sit-
ting position after 30 min of rest; measurements were taken
in 5-min intervals, and mean values were calculated. Body
mass index (BMI) was calculated as body weight × height−2
and expressed in kg/m2. The homeostasis model assess-
ment of insulin resistance (HOMA–IR) was calculated
according to the equation described by Matthews et al. [13]
The waist circumference (WC) was measured at the smal-
lest circumference between the rib cage and the iliac crest,
with the subject in the standing position.
Measurement of Osteoprotegerin, CRP and Adiponectin
Plasma samples were isolated from fasting subjects and
stored at -80 °C prior to analysis. The plasma OPG, C–
reactive protein(CRP) and adiponectin were determined in
duplicate by ELISA with Duoset kit (DY805, DY1707, and
DY1065; R&D Systems, Minneapolis, MN) as recom-
mended by the manufacturer. The ELISA system had an
intra-assay coefficient of variation of 3–9 % and an inter-
assay coefficient of variation of 4–10 %, respectively.
Determination of lower extremity arterial disease
The lower extremity arterial stenosis was characterized
using high-frequency color Doppler ultrasonic evaluation
(Philips, iU22, USA). Based on the criteria established by
the 2006 American Society of Echocardiography and the
Society of Vascular Medicine and Biology [14], the de-
gree of peripheral arterial diameter reduction was classi-
fied as “normal”(0 % diameter reduction of lower
extremity arterial stenosis, “mild” (1 –19 %), “moderate”
(20 –49 %), or “severe” (50 –99 %). Current and past
medical history, personal background, and medication
were recorded for all subjects.
Statistical analysis
The distribution of data was tested by the Kolmogorov-
Smirnov test. Normally distributed data were expressed
as means ± SD, whereas variables with a skewed distribu-
tion were reported as median (inter-quartile range) and
log transformed to approximate normality before ana-
lysis. Differences between groups were tested using the
unpaired Student’s t test or χ2 analysis, as appropriate.
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Pearson correlations were computed to assess the rela-
tionship between variables and OPG. Plasma OPG
levels were depicted according to the severity of lower
extremity arterial disease using linear regression model.
To investigate the association of the lower extremity
arterial disease with OPG, we defined participants with
normal lower extremity artery as 0 (n = 207) and the
lower extremity arterial disease as 1 (n = 505) in the
logistic regression analyses. Potential confounding
variables including age, gender and current smoking,
BMI, waist/hip ratio and HOMA-IR, SBP, DBP, CRP,
HbA1c, Triglycerides, total cholesterol, HDL-C and
LDL-C were controlled in the regression models. Data
management and statistical analysis were performed
with the SPSS Statistical Package (version 13.0; SPSS




There were 505 (70.9 %) patients with lower extremity
arterial stenosis and 207 (29.1 %) patients without
lower extremity arterial stenosis. Clinical, biochemical
and metabolic characteristics of participants of the
study were given in Table 1.
The plasma OPG levels were significantly increased
in patients with lower extremity arterial stenosis
[1.89 (1.48-2.41) vs. 2.39 (1.82-3.33) ng/mL, p < 0.001].
Plasma OPG levels correlated positively with age(r =
0.410, p < 0.001), duration of diabetes(r = 0.307, p <
0.001), SBP(r = 0.207, p < 0.001) and CRP(r = 0.247,
p < 0.001). Plasma OPG levels were not associated with
BMI, WC, DBP, FPG, HbA1C, uric acid, total choles-
terol, triglycerides, LDL-C, HDL-C and adiponectin
(Table 2).
Table 1 Characteristics of study population with or without lower extremity arterial stenosis
Without lower extremity arterial stenosis Lower extremity arterial stenosis p value
n 207 505 -
Age (years) 53.5 ± 12.1 65.3 ± 11.0 <0.001
Gender (male/female) 308/197 112/95 0.094
Duration of diabetes (years) 6.3 ± 5.9 10.6 ± 8.1 <0.001
smoking (%) 50 (24.3 %) 145 (28.7 %) 0.230
Hypertension (%) 86 (41.5 %) 326 (64.6 %) <0.001
BMI (kg/m2) 25.1 ± 4.2 24.6 ± 3.4 0.184
WC (cm) 94.2 ± 13.1 91.9 ± 11.3 0.106
SBP (mmHg) 130.2 ± 15.1 132.4 ± 15.4 0.199
DBP (mmHg) 78.6 ± 11.5 76.2 ± 9.5 0.038
FPG (mmol/l) 8.5 ± 3.3 8.6 ± 3.2 0.719
HbA1c (%) 9.7 ± 2.5 9.5 ± 2.3 0.490
(mmol/mol) 83 ± 19.8 80 ± 18.2 0.490
Serum uric acid (mmol/l) 300.3 ± 90.7 303.9 ± 89.0 0.724
Total cholesterol (mmol/l) 4.5 ± 1.1 4.7 ± 1.1 0.091
triglycerides (mmol/l) 1.54 (1.04–2.23) 1.55 (1.03–2.25) 0.962
LDL-c (mmol/l) 2.7 ± 0.8 2.9 ± 0.7 0.122
HDL-c (mmol/l) 1.4 ± 0.3 1.3 ± 0.3 0.203
Adiponectin (mg/l) 9.2 ± 5.7 6.7 ± 4.4 <0.001
CRP (mg/l) 1.75 (0.77–5.38) 2.43 (0.81–5.47) <0.001
Osteoprotegerin (ng/ml) 1.89 (1.48–2.41) 2.39 (1.82–3.33) <0.001
Hypoglycemic treatments 0.001
Insulin (%) 78 188
OHA (%) 100 186
Insulin + OHA (%) 29 131
Data are means ± SD, medians (interquartile range), or n (%). P values were obtained by an unpaired Student t test or χ2 analysis, as appropriate. BMI body mass
index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, LDL-c low-density lipoprotein cholesterol,
HDL-c high-density lipoprotein cholesterol, OHA oral hypoglycemic agent
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Association between OPG and severity of lower extremity
arterial stenosis
The median (inter-quartile range) of OPG concentrations
significantly increased for those with normal, mild, moder-
ate and severe was 1.83 (1.41–2.29), 2.02 (1.47–2.59), 2.41
(1.74–3.45), and 2.74 (2.13–3.65) ng/mL, respectively,
after adjustment for traditional cardiovascular risk factors
such as age, gender, smoking, total cholesterol, HDL-C,
CRP, BMI, and SBP (P < 0.001 for trend), (Fig. 1). The risk
of lower extremity arterial disease was increased (OR
= 1.17, 95 % CI 1.09-1.28, p < 0.001) with each SD
higher level of OPG in patients with type 2 diabetes
after adjustment for traditional CVD risk factors
(Table 3).
Discussion
In this study, we found a strong association between plasma
OPG levels and the risk of lower extremity arterial disease
in patients with type 2 diabetes. Moreover, this association
was independent of traditional CVD risk factors.
OPG was generally considered to be a secreted soluble
receptor and was produced by many different tissues
and cell types including osteoblasts. Moreover, OPG was
produced by cells of the cardiovascular system, including
coronary artery smooth muscle cells and endothelial
cells, suggesting that alterations of plasma OPG levels
may be associated with various atherosclerotic diseases,
including endothelial dysfunction, arterial stiffness, aor-
tic atheroma, carotid intima media thickness, and coron-
ary artery disease [15–18]. In line with previous studies
[9, 10], our findings also demonstrated that OPG had
significant association with lower extremity arterial
stenosis, diagnosed by high-frequency color Doppler
ultrasonic, in patients with type 2 diabetes. In our
study, with lower extremity arterial stenosis patients
had significantly elevated plasma OPG concentrations
compared with their control counterparts. Our findings,
which demonstrated the association between OPG and the
severity of lower extremity arterial stenosis, suggest that
OPG is a potential biomarker of lower extremity arterial
stenosis in type 2 diabetes. Measurement of plasma OPG
could be useful for lower extremity arterial stenosis stratifi-
cation of type 2 diabetes.
Table 2 Correlation between plasma osteoprotegerin (OPG)
levels and biochemical parameters
r p value
Age 0.410 <0.001






HbA1c (%) 0.020 0.680
Serum uric acid 0.005 0.906






BMI body mass index, WC waist circumference, SBP systolic blood pressure,
DBP diastolic blood pressure, FPG fasting plasma glucose, LDL-c low-density
lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol
Fig. 1 Plasma OPG levels in type 2 diabetes without lower
extremity arterial stenosis (Normal) compared with patients with
mild-, moderate-, or severe lower extremity arterial stenosis. Boxes
represent the 95 % confidence intervals, with the mean
superimposed as a horizontal line. Error bars indicate ranges of
plasma OPG levels. p < 0.001 for trend
Table 3 The risk of lower extremity arterial stenosis associated
with 1 SD increase in plasma OPG
Model Adjustment lower extremity
arterial stenosis
[OR, (95 % CI)]
p value
Model 1 Unadjusted 1.39 (1.23–1.54) <0.001
Model 2 Adjusted for age, gender
and current smoking
1.35 (1.18–1.49) <0.001













1.17 (1.09 –1.28) <0.001
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The clear mechanism for the vascular effects of OPG
is unknown, however, emerging evidence indicates OPG
may act as a protective factor for vascular diseases. One
hypothesis is that increased serum OPG levels may be a
compensatory self-defensive response to the progression
of atherosclerosis [8, 19]. It was well-documented that
OPG exerts its function through binding and neutralizing
the receptor activator for RANK/RANKL system [20].
RANKL can promote an osteogenic differentiation program
in vascular smooth muscle cell and stimulate chemokine
release, matrix metalloproteinases (MMP)-9 activity, and
monocyte/macrophage matrix migration [21]. OPG func-
tions as a soluble decoy receptor for receptor activator of
RANK ligand (RANKL or OPG ligand), thereby OPG may
serve a protective role in the vascular system. However,-
some studies indicated OPG may play causal role in athero-
sclerotic disease. Furthermore, OPG is also a receptor for
the cytotoxic ligand TNF-related apoptosis inducing ligand
(TRAIL), a potent activator of apoptosis. Recently, OPG
has been identified as a survival factor for endothelial cells
by blocking TRAIL-induced apoptosis. The regulatory
mechanism of OPG on vascular calcification could promote
the progression and instability of atherosclerosis [22, 23].
Moreover, a serial of clinical studies have shown that ele-
vated OPG is associated with a higher risk for death and
worse clinical outcome in patients with cardiovascular dis-
ease [24, 25]. Furthermore, increased OPG level is an inde-
pendent risk factor for further progression of carotid
atherosclerosis in prospective studies [26]. Although we
could not determine whether OPG has a protective or pro-
moting role in lower extremity arterial stenosis by the limi-
tation of design of this study, our findings suggested that
the OPG might have a role as a biomarker to identifying
patient with lower extremity arterial stenosis.
We found that plasma OPG levels were positively cor-
related with age, duration of diabetes, SBP, CRP. OPG
was not associated with BMI, WC, DBP, FPG, HbA1c,
uric acid, total cholesterol, triglycerides, LDL-C, HDL-C
and adiponectin. The positive relation we found between
OPG and age confirmed the results of previous studies
in both men and women [27]. This finding suggested
that the factors associated with aging may regulate OPG
levels. Szulc et al. showed that the relation between
OPG and age was more relevant in men by age 40-45
years, at a time in life when age-dependent bone loss
begined [28]. The increasing serum OPG level with age-
ing could be interpreted as a compensatory mechanism
counteracting the age progression of bone resorption
and atherosclerosis.
To our knowledge, our study is the first one to look at
a relationship between OPG and the severity of lower
extremity arterial stenosis. However, this study had a
number of limitations. First, a prospective study is
needed to clarify the causal relationship between OPG
and lower extremity arterial stenosis. Second, the rela-
tively small sample size limits the generalizability of our
conclusions. Further studies looking at these relations in
larger populations such as old and young people should
be performed. Third is the fact that circulating concentra-
tions of biomarkers are influenced by a number of factors,
mostly unknown, and their usage should be validated in
each condition.
Conclusions
In summary, our data showed that, increased plasma OPG
levels were independently associated with the presence and
the severity of lower extremity arterial stenosis. This finding
suggested that plasma OPG levels were an important deter-
minant of lower extremity arterial atherosclerosis in
patients with type 2 diabetes. Although the exact patho-
physiologic effect of OPG on lower extremity arterial sten-
osis is unknown, our findings suggest that plasma OPG is a
potential biomarker for lower extremity arterial stenosis.
Further studies are warranted to determine the functional
role of OPG in the development of atherosclerosis in nor-
mal patients.
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